

Genotype	Optimal Regimens
1	GLE/PIB 8 wks a-TE with PEG/RBV, no cirrhosis 8 wks b-Cirrhosis and TE with non-NS5A DAA 12 wks c-ESRD 12 wks d-Post-LT <u>without</u> cirrhosis and KT 12 wks e-Not for post-LT or decomp
	SOF/LDV 12wks a-Naive, noncirrhotic, non-African-American, and <10 <sup>6</sup> copies 8 wks b-Decomp cirrhosis, or NS3A/PI+PEG-IFN/RBV TE with cirrhosis, or post-LT, add RBV* c-SOF/RBV TE, add RBV 12 wks, if cirrhosis, add RBV 24 wks
	SOF/VEL 12 wks a-Decomp cirrhosis, add RBV* b-Decomp cirrhosis, and SOF or NS5A failure, add RBV 24 wks
	EBV/GZV 12 wks a-In G1a check RAVs to NS5A, if + 16 wks b-NS3A/PI+PEG-IFN/RBV TE, add RBV, and if +RAVs to NS5A 16 wks c-ESRD 8-16 wks (depending on stage/treatment history) d-Not for post-LT or decomp
	SOF/VEL/VOX TE DAA failures 12wks a-G1a non-NS5A failures 12 wks b-Not for post-LT with cirrhosis or decomp
2	GLE/PIB 8 wks a-TE with PEG/RBV, no cirrhosis 8 wks b-Cirrhosis and TE with non-NS5A DAA 12 wks c-ESRD 8-16 wks (depending on stage/treatment history) d-Post-LT <u>without</u> cirrhosis and KT 12 wks e-Not for post-LT or decomp
	SOF/VEL 12 wks a-Decomp cirrhosis, add RBV
	SOF/VEL/VOX TE DAA failures 12 wks a-G1a non-NS5A failures 12 wks b-Not for post-LT with cirrhosis or decomp
3	GLE/PIB 8 wks a-Cirrhosis and TE with non-NS5A DAA 12 wks c-ESRD 12-16 wks (depending on stage/treatment history) c-Post-LT <u>without</u> cirrhosis and KT 12 wks d-Not for post-LT or decomp
	SOF/VEL 12 wks a-TE with PEG-IFN/RBV without cirrhosis 12 wks b-Naive and TE with PEG-IFN/RBV with cirrhosis 12 wks (if Y93H RAS negative) c-Decomp cirrhosis, or PEG-IFN/RBV or SOF/RBV TE, add RBV
	SOF/VEL/VOX 12 wks a-TE with NS5A 12 wks (consider RBV if cirrhosis)

	<p>b-Naive and TE with PEG-IFN/RBV with cirrhosis 12 wks (if Y93H RAS positive)  b-Not for post-LT with cirrhosis or decomp</p>
	<p>SOF/ EBV/GZV 12 wks  a-TE with PEG-IFN/RBV with cirrhosis  b-Not for post-LT or decomp</p>
4	<p>GLE/PIB 8 wks  a-TE with PEG/RBV, no cirrhosis 8 wks  b-Cirrhosis and TE with non-NS5A DAA 12 wks  c-ESRD 8-16 wks (depending on stage/treatment history)  d-Post-LT <u>without</u> cirrhosis and KT 12 wks  e-Not for post-LT or decomp cirrhosis</p>
	<p>SOF/LDV 12 wks  a-Decomp cirrhosis, add RBV*  b-PEG-IFN/RBV TE and cirrhosis, add RBV*  c-SOF TE, add RBV</p>
	<p>EBV/GZV 12 wks  a-ESRD 12 wks  b-Not for post-LT or decomp</p>
	<p>SOF/VEL 12 wks  a-Decomp cirrhosis, add RBV*  b-SOF or NS5A TE, add RBV 24 wks</p>
	<p>SOF/VEL/VOX for TE DAA failures 12 wks  a-Not for decomp or LT with cirrhosis</p>
5, 6	<p>GLE/PIB 8 wks  a-TE with PEG/RBV, no cirrhosis 8 wks  b-Cirrhosis and TE with non-NS5A DAA 12 wks  c-ESRD 8-16 wks (depending on stage/treatment history)  d-Post LT without cirrhosis and KT 12 wks  e-Not for post-LT or decomp</p>
	<p>SOF/LDV 12 wks  a-SOF TE 24 wks add RBV  b-Post-LT, add RBV  c-Decomp, add RBV</p>
	<p>SOF/VEL 12 wks  a-If decomp, add RBV*  b-If DAA failure extend to 24 wks add RBV</p>
	<p>SOF/VEL/VOX for TE DAA failures 12 wks  a- Not for decomp or LT with cirrhosis</p>

© 2018 Mayo Foundation for Medical Education and Research. All rights reserved.

Cirrhosis refers to compensated except where decomp noted. \*If RBV intolerant, extend duration of treatment to 24 weeks.

Abbreviations: TE, treatment experienced; EBV, elbasvir; GPV, glecaprevir; GZV, grazoprevir; PBV, pibrentasvir; SOF, sofosbuvir; LDV, ledipasvir; VEL, velpatasvir; VOX, voxilaprevir; RBV, ribavirin.